Novo raises 2023 outlook due to higher than expected Ozempic and Wegovy sales in the US

No­vo Nordisk is rais­ing its sales and op­er­at­ing prof­it es­ti­mates for the year thanks to its di­a­betes and an­ti-obe­si­ty semaglu­tide prod­ucts We­govy and Ozem­pic, the com­pa­ny an­nounced Fri­day ahead of its full re­port set to re­lease on Nov. 2.

In the first nine months of this year at cur­rent ex­change rates, No­vo’s sales in­creased by 33%, and op­er­at­ing prof­it in­creased by 37% af­ter raised ex­pec­ta­tions for Ozem­pic sales in the US and gross-to-net sales ad­just­ments for both Ozem­pic and We­govy in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.